Back
EAPC Premium Access

Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis

Session: Poster Session II - Friday 08:30 - 18:00 - Diabetes/ Lipids/Obesity/Nutrition_Part 2
Topic: Lipids
Speaker: Mr M. Poudel (Bielefeld, DE)
Event: EuroPrevent 2017

Congress Presentation

Add to my library

Like

About the speaker

Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)
2 presentations
1 follower

12 more presentations in this session

Diabetes/ Lipids/Obesity/Nutrition_Part 2 - Poster discussant:.

Access
Like
Thumbnail

Atrial fibrillation preventive effect of n-3 polyunsaturated fatty acids in patients with hypertension

Speaker: Doctor S. Okamoto (Tsu, JP)

Access
Abstract
Like
Thumbnail

High rate of achievement of target values in LDL-cholesterol reduction through cardiac rehabilitation in patients with acute coronary syndrome

Speaker: Professor B. Schwaab (Timmendorfer Strand, DE)

Access
Abstract
Like
Thumbnail

Predictors of non-coronary aterosclerosis progression one year after coronary surgery

Speaker: Professor O. Barbarash (Kemerovo, RU)

Access
Abstract
Like
Thumbnail

Benefit of the PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis

Access
Like
Thumbnail

Access the full session

Poster Session II - Friday 08:30 - 18:00 - Diabetes/ Lipids/Obesity/Nutrition_Part 2

Speakers: Mr M. Poudel, Doctor S. Okamoto, Professor B. Schwaab, Professor O. Barbarash
Access
Like
Thumbnail

About the event

Image

EuroPrevent 2017

6 April - 8 April 2017

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources